Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 7,718 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Level 2 Clear all
Terminated Phase 2 Interventional Results available

Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)

NCT01924169
View directory record Official record
Conditions
Hematologic Disorder
Interventions
Lenalidomide, Influenza Vaccine, Pneumovax Vaccine
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693

NCT05919069
View directory record Official record
Conditions
Hepatic Impairment
Interventions
AZD2693
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Rialto, California • Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 21, 2026, 6:50 AM EDT
Active, not recruiting Phase 1 Interventional

Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors

NCT05334329
View directory record Official record
Conditions
Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Antineoplastic Immune Cell, Atezolizumab, Biospecimen Collection, Cyclophosphamide, Fludarabine
Biological · Procedure · Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Phase 2 Interventional

Honest Open Proud for Adolescents With Mental Illness

NCT02751229
View directory record Official record
Conditions
Secrecy Versus Disclosure Among Adolescents With Mental Illness
Interventions
Honest Open Proud (HOP)
Behavioral
Lead sponsor
University of Ulm
Other
Eligibility
13 Years to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 21, 2026, 6:50 AM EDT
Recruiting Not applicable Interventional

Rigorous Evaluation of Let's Talk Birth Control

NCT06670066
View directory record Official record
Conditions
Sexual Behavior, Adolescent Behavior
Interventions
Let's Talk Birth Control
Behavioral
Lead sponsor
Child Trends
Other
Eligibility
15 Years to 24 Years · Female only
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Sioux City, Iowa • Mentor, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 21, 2026, 6:50 AM EDT
Active, not recruiting Not applicable Interventional

Intervening With Haitian Immigrants in the U.S. to Improve HIV Outcomes

NCT05947266
View directory record Official record
Conditions
HIV Infection Primary
Interventions
an adaptation of the iENGAGE
Behavioral
Lead sponsor
Florida International University
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 21, 2026, 6:50 AM EDT
Terminated Phase 2 Interventional

20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms (Study 165)

NCT01568229
View directory record Official record
Conditions
Schizophrenia
Interventions
AMG 747, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
17
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Long Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Phase 1 Interventional

Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma

NCT01473095
View directory record Official record
Conditions
Solid Tumor, Malignant Lymphoma, Tumor
Interventions
ARQ 092
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
7
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Learn How Different Amounts of the Study Medicine Called PF-06954522 Are Tolerated and Act in the Body in Healthy Adults

NCT06003777
View directory record Official record
Conditions
Healthy Participants
Interventions
PF-06954522, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Oct 21, 2026, 6:50 AM EDT
Recruiting Not applicable Interventional

Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders

NCT05929703
View directory record Official record
Conditions
Delirium, Neurocognitive Disorders, Mild Cognitive Impairment, Alzheimer Disease, Aging, Family Support, Family Members, Caregiver Burden, Implementation Science, Patient Satisfaction
Interventions
HELP, FAM-HELP
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
70 Years and older
Enrollment
1,900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Orange, California • Portland, Maine • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 21, 2026, 6:50 AM EDT
Active, not recruiting Early Phase 1 Interventional

Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot)

NCT04634227
View directory record Official record
Conditions
Sarcoma, Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma, Metastatic Bone Tumor, Bone Sarcoma
Interventions
Ascorbate
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 21, 2026, 6:50 AM EDT
Completed No phase listed Observational

Neurobehavioral Model of HIV in Injection Drug Users

NCT00198861
View directory record Official record
Conditions
Drug Abuse, HIV Infections
Interventions
Injection and Non-Injection Drug Users
Other
Lead sponsor
The City College of New York
Other
Eligibility
15 Years to 50 Years
Enrollment
836 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 2, 2016 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Phase 1 Interventional

Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies

NCT00703170
View directory record Official record
Conditions
Resistant Solid Malignancies
Interventions
Temsirolimus, Pegylated liposomal doxorubicin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 24, 2013 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Organ Level Uptake Repeatability of 124I AT-01 in Subjects With Systemic Amyloidosis

NCT05235269
View directory record Official record
Conditions
Amyloidosis
Interventions
124I-AT-01
Drug
Lead sponsor
Attralus, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Berkeley, California • Sacramento, California • San Jose, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 21, 2026, 6:50 AM EDT
Completed No phase listed Observational Results available

Impact of Patient Activation and Engagement on Patient-Centered Outcomes of Care in ACOs

NCT02287883
View directory record Official record
Conditions
Diabetes, Cardiovascular Disease
Interventions
Observational: Patient Activation and Engagement (PAE)
Other
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years to 82 Years
Enrollment
2,176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Berkeley, California • Torrance, California • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2017 · Synced Oct 21, 2026, 6:50 AM EDT
Terminated Phase 1 Interventional

Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ART

NCT06430905
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV) Infection
Interventions
HB-502 and HB-501 alternating 2-vector therapy Dose Level 1, HB-502 and HB-501 alternating 2-vector therapy Dose Level 2, Placebo
Biological · Other
Lead sponsor
Hookipa Biotech GmbH
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
Orlando, Florida • Decatur, Georgia • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Exploratory Investigation of a Supplement to Support Student Learning

NCT05528094
View directory record Official record
Conditions
Concentration Ability Impaired, Mental Fatigue
Interventions
GeniusDrops
Dietary Supplement
Lead sponsor
JoySpring
Other
Eligibility
5 Years to 12 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 21, 2026, 6:50 AM EDT
Terminated Phase 4 Interventional Results available

A Comparison of Propofol Versus Midazolam to Sedate Critically Brain Injury; Measurement of Cytokine Response and Assessment of Function

NCT01712477
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Intravenous sedation using propofol, Intravenous sedation with midazolam
Drug
Lead sponsor
Michigan State University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 21, 2026, 6:50 AM EDT
Recruiting Phase 1 Interventional

PrP-targeting siRNA Safety & Mechanism Study

NCT07444580
View directory record Official record
Conditions
Prion Disease
Interventions
PrP-siRNA
Drug
Lead sponsor
Broad Institute of MIT and Harvard
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
5
States / cities
Boston, Massachusetts • Rochester, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Phase 1 Interventional

A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

NCT04540796
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
JNJ-75348780
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Birmingham, Alabama • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Whole Body Hyperthermia and Major Depression (MDD)

NCT01625546
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Whole Body Hyperthermia system
Device
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 10, 2015 · Synced Oct 21, 2026, 6:50 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors

NCT01784861
View directory record Official record
Conditions
Adenocarcinoma, Pancreatic Neoplasms
Interventions
X-82, Everolimus
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
St Louis, Missouri • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia

NCT02733042
View directory record Official record
Conditions
Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
Durvalumab, Lenalidomide, Rituximab, Ibrutinib, Bendamustine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
19
States / cities
Gilbert, Arizona • Scottsdale, Arizona • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Not applicable Interventional

Virtual Reality and Anxiety in Pediatric Dentistry

NCT04886141
View directory record Official record
Conditions
Pediatric Dentistry
Interventions
Virtual Reality Headset
Behavioral
Lead sponsor
Geisinger Clinic
Other
Eligibility
4 Years to 12 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Oct 21, 2026, 6:50 AM EDT